Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression

Bettina H. Bewernick, René Hurlemann, Andreas Matusch, Sarah Kayser, Christiane Grubert, Barbara Hadrysiewicz, Nikolai Axmacher, Matthias Lemke, Deirdre Cooper-Mahkorn, Michael X. Cohen, Holger Brockmann, Doris Lenartz, Volker Sturm, Thomas E. Schlaepfer

Research output: Contribution to journalArticle

Abstract

Background: While most patients with depression respond to combinations of pharmacotherapy, psychotherapy, and electroconvulsive therapy (ECT), there are patients requiring other treatments. Deep brain stimulation (DBS) allows modulation of brain regions that are dysfunctional in depression. Since anhedonia is a feature of depression and there is evidence of dysfunction of the reward system, DBS to the nucleus accumbens (NAcc) might be promising. Methods: Ten patients suffering from very resistant forms of depression (treatment-resistant depression [TRD]), not responding to pharmacotherapy, psychotherapy, or ECT, were implanted with bilateral DBS electrodes in the NAcc. The mean (±SD) length of the current episode was 10.8 (±7.5) years; the number of past treatment courses was 20.8 (±8.4); and the mean Hamilton Depression Rating Scale (HDRS) was 32.5 (±5.3). Results: Twelve months following initiation of DBS treatment, five patients reached 50% reduction of the HDRS (responders, HDRS = 15.4 [±2.8]). The number of hedonic activities increased significantly. Interestingly, ratings of anxiety (Hamilton Anxiety Scale) were reduced in the whole group but more pronounced in the responders. The [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography data revealed that NAcc-DBS decreased metabolism in the subgenual cingulate and in prefrontal regions including orbital prefrontal cortex. A volume of interest analysis comparing responders and nonresponders identified metabolic decreases in the amygdala. Conclusions: We demonstrate antidepressant and antianhedonic effects of DBS to NAcc in patients suffering from TRD. In contrast to other DBS depression studies, there was also an antianxiety effect. These effects are correlated with localized metabolic changes.

Original languageEnglish (US)
Pages (from-to)110-116
Number of pages7
JournalBiological Psychiatry
Volume67
Issue number2
DOIs
StatePublished - Jan 15 2010

Fingerprint

Treatment-Resistant Depressive Disorder
Deep Brain Stimulation
Nucleus Accumbens
Anxiety
Depression
Electroconvulsive Therapy
Prefrontal Cortex
Psychotherapy
Anhedonia
Drug Therapy
Pleasure
Anti-Anxiety Agents
Fluorodeoxyglucose F18
Amygdala
Reward
Positron-Emission Tomography
Antidepressive Agents
Electrodes
Therapeutics
Brain

Keywords

  • Deep brain stimulation
  • functional neuroimaging
  • major depression
  • neuromodulation
  • nucleus accumbens
  • treatment resistance

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression. / Bewernick, Bettina H.; Hurlemann, René; Matusch, Andreas; Kayser, Sarah; Grubert, Christiane; Hadrysiewicz, Barbara; Axmacher, Nikolai; Lemke, Matthias; Cooper-Mahkorn, Deirdre; Cohen, Michael X.; Brockmann, Holger; Lenartz, Doris; Sturm, Volker; Schlaepfer, Thomas E.

In: Biological Psychiatry, Vol. 67, No. 2, 15.01.2010, p. 110-116.

Research output: Contribution to journalArticle

Bewernick, BH, Hurlemann, R, Matusch, A, Kayser, S, Grubert, C, Hadrysiewicz, B, Axmacher, N, Lemke, M, Cooper-Mahkorn, D, Cohen, MX, Brockmann, H, Lenartz, D, Sturm, V & Schlaepfer, TE 2010, 'Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression', Biological Psychiatry, vol. 67, no. 2, pp. 110-116. https://doi.org/10.1016/j.biopsych.2009.09.013
Bewernick, Bettina H. ; Hurlemann, René ; Matusch, Andreas ; Kayser, Sarah ; Grubert, Christiane ; Hadrysiewicz, Barbara ; Axmacher, Nikolai ; Lemke, Matthias ; Cooper-Mahkorn, Deirdre ; Cohen, Michael X. ; Brockmann, Holger ; Lenartz, Doris ; Sturm, Volker ; Schlaepfer, Thomas E. / Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression. In: Biological Psychiatry. 2010 ; Vol. 67, No. 2. pp. 110-116.
@article{7d8f69e76078492d97d66a9bb046a97d,
title = "Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression",
abstract = "Background: While most patients with depression respond to combinations of pharmacotherapy, psychotherapy, and electroconvulsive therapy (ECT), there are patients requiring other treatments. Deep brain stimulation (DBS) allows modulation of brain regions that are dysfunctional in depression. Since anhedonia is a feature of depression and there is evidence of dysfunction of the reward system, DBS to the nucleus accumbens (NAcc) might be promising. Methods: Ten patients suffering from very resistant forms of depression (treatment-resistant depression [TRD]), not responding to pharmacotherapy, psychotherapy, or ECT, were implanted with bilateral DBS electrodes in the NAcc. The mean (±SD) length of the current episode was 10.8 (±7.5) years; the number of past treatment courses was 20.8 (±8.4); and the mean Hamilton Depression Rating Scale (HDRS) was 32.5 (±5.3). Results: Twelve months following initiation of DBS treatment, five patients reached 50{\%} reduction of the HDRS (responders, HDRS = 15.4 [±2.8]). The number of hedonic activities increased significantly. Interestingly, ratings of anxiety (Hamilton Anxiety Scale) were reduced in the whole group but more pronounced in the responders. The [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography data revealed that NAcc-DBS decreased metabolism in the subgenual cingulate and in prefrontal regions including orbital prefrontal cortex. A volume of interest analysis comparing responders and nonresponders identified metabolic decreases in the amygdala. Conclusions: We demonstrate antidepressant and antianhedonic effects of DBS to NAcc in patients suffering from TRD. In contrast to other DBS depression studies, there was also an antianxiety effect. These effects are correlated with localized metabolic changes.",
keywords = "Deep brain stimulation, functional neuroimaging, major depression, neuromodulation, nucleus accumbens, treatment resistance",
author = "Bewernick, {Bettina H.} and Ren{\'e} Hurlemann and Andreas Matusch and Sarah Kayser and Christiane Grubert and Barbara Hadrysiewicz and Nikolai Axmacher and Matthias Lemke and Deirdre Cooper-Mahkorn and Cohen, {Michael X.} and Holger Brockmann and Doris Lenartz and Volker Sturm and Schlaepfer, {Thomas E.}",
year = "2010",
month = "1",
day = "15",
doi = "10.1016/j.biopsych.2009.09.013",
language = "English (US)",
volume = "67",
pages = "110--116",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression

AU - Bewernick, Bettina H.

AU - Hurlemann, René

AU - Matusch, Andreas

AU - Kayser, Sarah

AU - Grubert, Christiane

AU - Hadrysiewicz, Barbara

AU - Axmacher, Nikolai

AU - Lemke, Matthias

AU - Cooper-Mahkorn, Deirdre

AU - Cohen, Michael X.

AU - Brockmann, Holger

AU - Lenartz, Doris

AU - Sturm, Volker

AU - Schlaepfer, Thomas E.

PY - 2010/1/15

Y1 - 2010/1/15

N2 - Background: While most patients with depression respond to combinations of pharmacotherapy, psychotherapy, and electroconvulsive therapy (ECT), there are patients requiring other treatments. Deep brain stimulation (DBS) allows modulation of brain regions that are dysfunctional in depression. Since anhedonia is a feature of depression and there is evidence of dysfunction of the reward system, DBS to the nucleus accumbens (NAcc) might be promising. Methods: Ten patients suffering from very resistant forms of depression (treatment-resistant depression [TRD]), not responding to pharmacotherapy, psychotherapy, or ECT, were implanted with bilateral DBS electrodes in the NAcc. The mean (±SD) length of the current episode was 10.8 (±7.5) years; the number of past treatment courses was 20.8 (±8.4); and the mean Hamilton Depression Rating Scale (HDRS) was 32.5 (±5.3). Results: Twelve months following initiation of DBS treatment, five patients reached 50% reduction of the HDRS (responders, HDRS = 15.4 [±2.8]). The number of hedonic activities increased significantly. Interestingly, ratings of anxiety (Hamilton Anxiety Scale) were reduced in the whole group but more pronounced in the responders. The [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography data revealed that NAcc-DBS decreased metabolism in the subgenual cingulate and in prefrontal regions including orbital prefrontal cortex. A volume of interest analysis comparing responders and nonresponders identified metabolic decreases in the amygdala. Conclusions: We demonstrate antidepressant and antianhedonic effects of DBS to NAcc in patients suffering from TRD. In contrast to other DBS depression studies, there was also an antianxiety effect. These effects are correlated with localized metabolic changes.

AB - Background: While most patients with depression respond to combinations of pharmacotherapy, psychotherapy, and electroconvulsive therapy (ECT), there are patients requiring other treatments. Deep brain stimulation (DBS) allows modulation of brain regions that are dysfunctional in depression. Since anhedonia is a feature of depression and there is evidence of dysfunction of the reward system, DBS to the nucleus accumbens (NAcc) might be promising. Methods: Ten patients suffering from very resistant forms of depression (treatment-resistant depression [TRD]), not responding to pharmacotherapy, psychotherapy, or ECT, were implanted with bilateral DBS electrodes in the NAcc. The mean (±SD) length of the current episode was 10.8 (±7.5) years; the number of past treatment courses was 20.8 (±8.4); and the mean Hamilton Depression Rating Scale (HDRS) was 32.5 (±5.3). Results: Twelve months following initiation of DBS treatment, five patients reached 50% reduction of the HDRS (responders, HDRS = 15.4 [±2.8]). The number of hedonic activities increased significantly. Interestingly, ratings of anxiety (Hamilton Anxiety Scale) were reduced in the whole group but more pronounced in the responders. The [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography data revealed that NAcc-DBS decreased metabolism in the subgenual cingulate and in prefrontal regions including orbital prefrontal cortex. A volume of interest analysis comparing responders and nonresponders identified metabolic decreases in the amygdala. Conclusions: We demonstrate antidepressant and antianhedonic effects of DBS to NAcc in patients suffering from TRD. In contrast to other DBS depression studies, there was also an antianxiety effect. These effects are correlated with localized metabolic changes.

KW - Deep brain stimulation

KW - functional neuroimaging

KW - major depression

KW - neuromodulation

KW - nucleus accumbens

KW - treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=71649103156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71649103156&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2009.09.013

DO - 10.1016/j.biopsych.2009.09.013

M3 - Article

C2 - 19914605

AN - SCOPUS:71649103156

VL - 67

SP - 110

EP - 116

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 2

ER -